Colangiocarcinoma on the rise!
|
|
|
- Sandra Brooks
- 5 years ago
- Views:
Transcription
1 Colangiocarcinoma on the rise! D. ALVARO, Univ. Sapienza, Rome, Italy. MONOTEMATICA AISF, The future of Liver Diseases, Milano Ottobre 2016
2 Domenico ALVARO, MD. SAPIENZA, ROMA Il sottoscritto dichiara di non aver avuto/di aver avuto negli ultimi 12 mesi conflitto d interesse in relazione a questa presentazione e che la presentazione non contiene/contiene discussione di farmaci in studio o ad uso off-label
3 CHOLANGIOCARCINOMA (CCA): a more recent classification based on anatomic location (EASL, ILCA guidelines 2013/2014, ENS-CCA)) This classification overcomes the difficulties in classifying pcca INTRAHEPATIC Therefore, as intra- or CCA extra-hepatic classification in icca, (icca) pcca, dcca is clinically useful but % In ICD-O3, second-order CCA is bile topographically ducts classified as but.. Klatskin t. C22 liver and intrahepatic bile ducts or clashes C24 with other current and epidemiologic unspecified parts of the biliary tract. studies including risk factors! Current epidemiological data evaluate only icca and ecca! Distal (dcca) 2-5% Perihilar (pcca) 70-85%
4 CCA: Worldwide incidence (cases/100,000), Banales JM Alvaro D. Nature Rev
5 Temporal trends in IH- and EH-CCA incidence/mortality in In different countries, yrs incidence/mortality Real or false increasing incidence of IH-CCA? for IH-CCA Bias??? = for EH-CCA
6 Real or false increasing incidence of IH-CCA? Bias??? The reported increasing incidence of IH-CCA is biased by: - misclassification of perihilar-cca as IH-CCA? - improved diagnostic tools? - less diagnosis of carcinoma of unknown primary site (CUP).
7 CHOLANGIOCARCINOMA: epidemiology! Biases and criticisms! Morphology Morphology+ topography Italian Cancer registries IH-CCA (Capocaccia P. et al. DLD 2010) IH-CCA = % EH-CCA = % NOS = 20-40% USA SEER-9 registries, Welzel TM et al. (J Natl Cancer Inst 2006) EH-CCA ICD-02: overreporting of IH-CCA by 13% underreporting of EH-CCA by 15 %
8 90 % Klatskin..as ICC % SEER registries (9,840 CC cases, )
9
10 tasso standardizzato x milione TASSI DI INCIDENZA STANDARDIZZATI PER IH-CCA ED EH-CCA NELLE POPOLAZIONI OSSERVATE DA 9 REGISTRI (PERIODO ) E DA 13 REGISTRI (PERIODO ) ITALIANI. (Alvaro D. et al. DLD 2009) 20,0 18,0 9 registri 13 registri Extra-Epatico 16,0 14,0 12,0 + 3%/anno 10,0 8,0 Intra-Epatico 6,0 4,0 2,0 0,0 + 6%/anno + 4%/anno anno di diagnosi
11 Cancer Deaths in USA in 2030 Liver and intrahepatic bile ducts
12 2014
13 Real or false increasing incidence of IH-CCA? Bias??? The reported increasing incidence of IH-CCA is biased by: - misclassification of perihilar-cca as IH-CCA? - improved diagnostic tools? - less diagnosis of carcinoma of unknown primary site (CUP).
14 The proportion of patients with different disease stages shown in successive 5-year cohorts(shaib Y. J. Hepatology 2004).
15 Real or false increasing incidence of IH-CCA? Bias??? The reported increasing incidence of IH-CCA is biased by: - missclassification of perihilar-cca as IH-CCA? - improved diagnostic tools? - less diagnosis of carcinoma of unknown primary site (CUP).
16
17 American Hepato-Pancreato-Biliary Association
18 92-gene biomarker panel (RT-PCR based protocol) and computational approach.
19 ICCs N HCC N. 42 Non hepatic origin N. 332 American Hepato-Pancreato-Biliary Association (perihilar-cca, pancreas, stomach, esophagus, colon, breast, ovary, endometrium, 22 % of kidney, previously and urinary diagnosed bladder) CUP tested positive for albumin-rna! Albumin RNA ISH positive in 82 (99 %) ICCs and in IH-CCA 22% of CUP 42!!!!!!! (100 %) HCC Perihilar and distal-cca = 100% negative
20 Real or false increasing incidence of IH-CCA? Bias??? The reported increasing incidence of IH-CCA is biased by: - misclassification of perihilar-cca as IH-CCA? - improved diagnostic tools? - less diagnosis of carcinoma of unknown primary site (CUP).
21 Real increasing incidence of IH-CCA! Why??
22 A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. Palmer WC, Patel T. J. Hepatology AISF commissione colangiocarcinoma, DLD O.Viverrini pcca IH-CCA EH-CCA C. Sinensis n= 116 n= 102 Cirrhosis 16 (13.8%) 5 (4.3%) PSC Cirrhosis viral 12 (10.3%) 3 (2.9%) Choledochal cysts, Caroli s HCV-Ab+ 18 (15.5%) 8 (7.8%) Thorotrast HBsAg+ 17 (14.6%) 10 (9.8%)
23 Human Diabetes Experimental Diabetes Metabolic Syndrome and Gastrointestinal Cancer Risk! Working Hypothesis Activation of stem/progenitor cells in PBGs, pancreatic duct glands and colon crypts, and differentiation toward insulinproducing cells, could represent the biologic basis for GI cancer risk?
24 CCA risk factors icca pcca n= 116 n= 102 Positive hepatitis virus markers 35 (30.2%) 19 (18.6%) p= No putative risk factor in 60% CCA!
25 CCA: probable risk factors Hepatic Schistosmiasis Liver Cirrhosis IBD Cholelithiasis/cholecystectomy EH-CCA Biliary-enteric drainage Toxins: dioxins, asbestos Choledocolithiasis Cholangitis IH-CCA Diabetes, Alcohol Obesity, tobacco
26
27
28 Chronic inflammation and CCA Chronic Inflammation (flukes,psc..) IL6 TNF inos NO COX-2 PgE2 Apoptosis Proliferation Nitrosylation DNA basis and DNA repair proteins, caspase 9 Mutagenesis
29
30
31 Acknowledgments Prof. P. Berloco Prof. M. Nuti/Dr. Napolitano Prof. A.F. Attili/Prof. A. DeSantis Prof. E. Gaudio Thanks for the attention Dr G. Carpino Prof L. Reid at UNC Dr V. Cardinale
Liver transplant: what is left after the viruses
Riunione Monotematica A.I.S.F. 2016 The Future of Liver Disease: Beyond HCV is there a Role for Hepatologist? Milan 15 th 2016 Liver transplant: what is left after the viruses Stefano Ginanni Corradini
Pazienti con Genotipo 1 e Cirrosi Scompensata, pre-/post-olt
Monotematica AISF 2013 Pazienti con Genotipo 1 e Cirrosi Scompensata, pre-/post-olt Pietro Andreone Dipartimento di Scienze Mediche e Chirurgiche Alma Mater Studiorum, Università di Bologna Pisa, 17-19
Monitoring trends in Cholangiocarcinoma Why Coding is Important
Monitoring trends in Cholangiocarcinoma Why Coding is Important Dr Shahid A Khan St Mary s Hospital Imperial College London AMMF Cholangiocarcinoma Conference 10 th May 2018 1 Cholangiocarcinoma (CCA)
Prototypes of autoimmune hepatitis and sclerosing cholangitis in childhood
RIUNIONE MONOTEMATICA AISF 2013 Personalizzazione della Cura in Epatologia 17-19 ottobre 2013, PISA Prototypes of autoimmune hepatitis and sclerosing cholangitis in childhood La sottoscritta dichiara di
Diagnostic Procedures. Measurement of Hepatic venous pressure in management of cirrhosis. Clinician s opinion
5 th AISF Post-Meeting Course Diagnostic and Therapeutic Invasive Procedures in Hepatology Rome, February 25 th Diagnostic Procedures Measurement of Hepatic venous pressure in management of cirrhosis Clinician
Alcoholic Liver Disease as First Indication
Alcoholic Liver Disease as First Indication Patrizia Burra Multivisceral Transplant Unit Gastroenterology Department of Surgery, Oncology and Gastroenterology Padua University Hospital, Padua, Italy Patrizia
Future of stem cell therapy in liver disease Domenico ALVARO, MD Sapienza, University of Rome, Italy
Future of stem cell therapy in liver disease Domenico ALVARO, MD Sapienza, University of Rome, Italy AISF, 17 th Pre Meeting Future Scenarios in Hepatology, 18-02-2015. CELL THERAPY and LIVER DISEASES
Filippo Schepis, MD Università degli Studi di Modena e Reggio Emilia
Filippo Schepis, MD Università degli Studi di Modena e Reggio Emilia Il sottoscritto dichiara di non aver avuto/di aver avuto negli ultimi 12 mesi conflitto d interesse in relazione a questa presentazione
Cholangiocellular carcinoma. Dr. med. Henrik Csaba Horváth PhD
Cholangiocellular carcinoma Dr. med. Henrik Csaba Horváth PhD Acalculous biliary diseases April 12, 2017 2 Cholangiocarcinoma A slow growing malignancy of the biliary tract which tend - to infiltrate locally
Role of Nutritional Support in the Treatment of Alcoholic Liver Disease
Riunione Monotematica AISF Alcoholic Liver Disease: The New Challenge Roma, 4-6 Ottobre 2017 Role of Nutritional Support in the Treatment of Alcoholic Liver Disease Esmeralda Capristo Divisione di Patologie
Invasive Evaluation of Portal Hypertension. Vincenzo La Mura, MD PhD Department of Biomedical Sciences for Health University of Milan
Invasive Evaluation of Portal Hypertension Vincenzo La Mura, MD PhD Department of Biomedical Sciences for Health University of Milan Vincenzo La Mura, MD, PhD Dipartimento di scienze Biomediche per la
Towards Precision Medicine in Primary Biliary Cholangitis
Riunione Monotematica A.I.S.F. 2016 THE FUTURE OF LIVER DISEASES: Beyond HCV is there a role for the hepatologist? 14 th October 2016 Towards Precision Medicine in Primary Biliary Cholangitis Marco Carbone,
Hepatocellular carcinoma: Intra-arterial treatments
Hepatocellular carcinoma: Intra-arterial treatments Irene Bargellini U.O. Radiologia Interventistica Azienda Ospedaliero Universitaria Pisana IRENE BARGELLINI,MD UO RADIOLOGIA INTERVENTISTICA, AZIENDA
Staging and prognostic systems: beyond BCLC?
Staging and prognostic systems: beyond BCLC? Alessandro Vitale, MD, PhD, FEBS U.O.C. di Chirurgia Epatobiliare e dei Trapianti Epatici, Department of Surgery, Oncology and Gastroenterology, University
Riunione Monotematica AISF 2017 Roma 5 Ottobre Management of Alcohol Use Disorders in Patients with Alcoholic Liver Disease
Riunione Monotematica AISF 2017 Roma 5 Ottobre 2017 Management of Alcohol Use Disorders in Patients with Alcoholic Liver Disease Lorenzo Leggio, M.D., Ph.D., M.Sc. Lorenzo Leggio, M.D., Ph.D., M.Sc. Il
Pierluigi Toniutto Clinica di Medicina Interna Azienda Ospedaliero Universitaria Udine
Pierluigi Toniutto Clinica di Medicina Interna Azienda Ospedaliero Universitaria Udine Il sottoscritto dichiara di non aver avuto negli ultimi 12 mesi conflitto d interesse in relazione a questa presentazione
CHOLANGIOCARCINOMA (CCA)
CHOLANGIOCARCINOMA (CCA) Deepak Hariharan MD (Research), FRCS, Locum Consultant HPB Surgeon AIM Outline essential facts & principles Present 4 cases Discuss Challenges /Controversies INTRODUCTION Most
Hepatocellular carcinoma: from guidelines to individualized treatment
AISF 2012 Rome, 22-24 February 2012 Hepatocellular carcinoma: from guidelines to individualized treatment A.D. 1088 Luigi Bolondi Professor of Medicine, Chairman Department of Digestive Diseases and Internal
Umberto Volta Coeliac Disease and Malbsorption Unit Digestive Diseases and Internal Medicine Dept St.Orsola-Malpighi Hospital, Bologna
Coeliac disease Umberto Volta Coeliac Disease and Malabsorption Unit Digestive Diseases and Internal Medicine Dept. St. Orsola-Malpighi Hospital University of Bologna President of the Scientific Board
6 Riunione Monotematica A.I.S.F NASH malattia epatica, oncologica e cardiovascolare
6 Riunione Monotematica A.I.S.F. 2015 NASH malattia epatica, oncologica e cardiovascolare Modena, 9 ottobre 2015 Massimo Colombo NAFLD e HCC: caratteristiche distintive Chairman Department of Liver, Kidney,
Markers of Alcohol Abuse in Alcoholic Liver Disease: sensitivity and specificity. Alessandro Federico University of Campania L.
Markers of Alcohol Abuse in Alcoholic Liver Disease: sensitivity and specificity Alessandro Federico University of Campania L. Vanvitelli Alessandro Federico Markers of Alcohol Abuse in Alcoholic Liver
A patient with acute on chronic liver failure
A patient with acute on chronic liver failure Dott.ssa Marta Cavallin Dept. of Medicine of University of Padova, Italy 6 th Post Meeting AISF Rome, 23 rd February 2013 Dott.ssa Marta Cavallin medico in
The Norwegian PSC Research Center Biobank
The Norwegian PSC Research Center Biobank Trine Folseraas Norwegian PSC Research Center, Department of Transplantation Medicine, Division of Surgery, Inflammatory Medicine and Transplantation, Oslo University
NAFLD: The role of genetics
NAFLD: The role of genetics Luca Valenti Department of Pathophysiology and Transplantation, Università degli Studi di Milano Internal Medicine, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
Complication of Portal Hypertension: should the patients in the waiting list be treated differently?
Wilma Debernardi Venon Gastroepatologia, Az. Osp. San Giovanni Battista ditorino Complication of Portal Hypertension: should the patients in the waiting list be treated differently? Il sottoscritto dichiara
R.Sotoudehmanesh, MD Professor of Gastroenterology Digestive Disease Research Institute Tehran University of Medical Sciences Pancreatobiliary
R.Sotoudehmanesh, MD Professor of Gastroenterology Digestive Disease Research Institute Tehran University of Medical Sciences Pancreatobiliary /Advanced Endoscopy group Most common biliary malignancy and
Ablazione chirurgica e trapianto
Unità di Chirurgia Epatobiliare e Trapianto Epatico Azienda Università di Padova Personalizzazione dell indicazione terapeutica Ablazione chirurgica e trapianto Prof. Umberto Cillo cillo@unipd.it Umberto
The Cancer Burden in California. Janet Bates MD MPH California Cancer Registry California Department of Public Health April 25, 2012
The Cancer Burden in California Janet Bates MD MPH California Cancer Registry California Department of Public Health April 25, 2012 Goals Introduce you to the California Cancer Registry (CCR) Provide an
Perché viene la NASH (2): microbiota e permeabilità intestinale G. Svegliati-Baroni
Perché viene la NASH (2): microbiota e permeabilità intestinale G. Svegliati-Baroni Clinica di Gastroenterologia SOS Epatopatie Croniche e Trapianto di Fegato Università Politecnica delle Marche Ancona
Hilar cholangiocarcinoma. Frank Wessels, Maarten van Leeuwen, UMCU utrecht
Hilar cholangiocarcinoma Frank Wessels, Maarten van Leeuwen, UMCU utrecht Content Anatomy Biliary strictures (Hilar) Cholangiocarcinoom Staging Biliary tract 1 st order Ductus hepatica dextra Ductus hepaticus
Types of Cholangiocarcinoma
Colangiocarcinoma Types of Cholangiocarcinoma Peripheral Perihilar Distal 20-30% Intrahepatic mass Cirrhosis uncommon 40-60% Biliary confluence Most common 20-30% 10-15% of peripancreatic tumors Epidemiology
Cholangiocarcinoma. GI Practice Guideline. Michael Sanatani, MD, FRCPC (Medical Oncologist) Barbara Fisher, MD, FRCPC (Radiation Oncologist)
Cholangiocarcinoma GI Practice Guideline Michael Sanatani, MD, FRCPC (Medical Oncologist) Barbara Fisher, MD, FRCPC (Radiation Oncologist) Approval Date: October 2006 This guideline is a statement of consensus
Navigating the Biliary Tract with CT & MR: An Imaging Approach to Bile Duct Obstruction
Navigating the Biliary Tract with CT & MR: An Imaging Approach to Bile Duct Obstruction Ann S. Fulcher, MD Medical College of Virginia Virginia Commonwealth University Richmond, Virginia Objectives To
BOCEPREVIR (BOC): EVIDENCE FROM TRIALS
BOCEPREVIR (BOC): EVIDENCE FROM TRIALS ROME, FEBRUARY 22 nd -25 th, 212 Savino Bruno, MD Department of Internal Medicine A.O. Fatebenefratelli e Oftalmico Milan, Italy Savino Bruno, MD Director of InternalMedicine,
EPITHELIAL TUMOURS OF OESOPHAGUS RARE EPITHELIAL TUMOURS OF STOMACH EPITHELIAL TUMOURS OF SMALL INTESTINE RARE EPITHELIAL TUMOURS OF COLON
RARE EPITHELIAL TUMOURS OF THE DIGESTIVE SYSTEM 16% OF DIGESTIVE SYSTEM TUMOURS ARE RARE EPITHELIAL TUMOURS 2 262 271 EPITHELIAL TUMOURS OF OESOPHAGUS RARE EPITHELIAL TUMOURS OF STOMACH 81 1 % OF RARE
Epidemiology in Texas 2006 Annual Report. Cancer
Epidemiology in Texas 2006 Annual Report Cancer Epidemiology in Texas 2006 Annual Report Page 94 Cancer Incidence and Mortality in Texas, 2000-2004 The Texas Department of State Health Services Texas Cancer
Cholangiocarcinoma. Judy Wyatt Dundee November 2010
Cholangiocarcinoma Judy Wyatt Dundee November 2010 Making sense of cholangiocarcinoma Difficulties with diagnostic criteria How many entities within cholangiocarcinoma? Rapidly evolving Intrahepatic cholangiocarcinoma
Changing epidemiology of HCC in Italy
Changing epidemiology of HCC in Italy G. Svegliati-Baroni Clinica di Gastroenterologia SOS Epatopatie Croniche-Trapianto di Fegato Università Politecnica delle Marche, Ancona Worldwide estimated new PLC
Biliary Atresia. Karen F. Murray, MD Professor of Pediatrics Director, Hepatobiliary Program Seattle Children s
Biliary Atresia Karen F. Murray, MD Professor of Pediatrics Director, Hepatobiliary Program Seattle Children s Biliary Atresia Incidence: 1/8,000-15,000 live births Girls > boys 1.5:1 The most common cause
TIPS in the Management of Portal Hypertension Clinician s Opinion
TIPS in the Management of Portal Hypertension Clinician s Opinion Oliviero Riggio 5 th AISF post meeting course Diagnostic and Therapeutic Procedures in Hepatology 2012 Oliviero Riggio Dipartimento di
New insights into cholangiocarcinoma: multiple stems and related cell lineages of origin
INVITED REVIEW Annals of Gastroenterology (2018) 31, 1-14 New insights into cholangiocarcinoma: multiple stems and related cell lineages of origin Maria Consiglia Bragazzi, Lorenzo Ridola, Samira Safarikia,
What is Liver Cancer? About the Liver
Your liver is important and it has many functions. The top three are that it cleans your blood of toxins, gives you energy and produces bile for digestion. What is Liver Cancer? Cancer starts when cells
Cholangiocarcinoma (CCA), a cancer arising. Aspirin Use and the Risk of Cholangiocarcinoma SEE EDITORIAL ON PAGE 708
AMERICAN ASSOCIATION FOR THE STUDY OFLIVERD I S E ASES HEPATOLOGY, VOL. 64, NO. 3, 2016 Aspirin Use and the Risk of Cholangiocarcinoma Jonggi Choi, 1 Hassan M. Ghoz, 1 Thoetchai Peeraphatdit, 1,2 Esha
Supplementary Online Content
Supplementary Online Content Chacón MR, Enrico DH, Burton J, Waisberg FD, Videla VM. Incidence of placebo adverse events in randomized clinical trials of targeted and immunotherapy cancer drugs in the
ANNUAL CANCER REGISTRY REPORT-2005
ANNUAL CANCER REGISTRY REPORT-25 CANCER STATISTICS Distribution of neoplasms Of a total of 3,115 new neoplasms diagnosed or treated at the Hospital from January 25 to December, 25, 1,473 were seen in males
Tratamiento endoscópico de la CEP. En quien como y cuando?
Tratamiento endoscópico de la CEP. En quien como y cuando? Andrés Cárdenas, MD, MMSc, PhD, AGAF, FAASLD GI / Liver Unit, Hospital Clinic Institut de Malalties Digestives i Metaboliques University of Barcelona
II BIENNAL CONGRESS of the. European Network for the Study of Cholangiocarcinoma (ENS-CCA) Rome Italy
II BIENNAL CONGRESS of the European Network for the Study of Cholangiocarcinoma (ENS-CCA) Rome Italy June 21 st 22 nd 23 rd - 2018 II BIENNAL CONGRESS of the European Network for the Study of Cholangiocarcinoma
Natural History of Alcoholic Liver Disease: Role of Hepatitis C, Environmental, Genetic Factors and Gender Differences
Natural History of Alcoholic Liver Disease: Role of Hepatitis C, Environmental, Genetic Factors and Gender Differences AISF Monothematic Conference, Rome October 5th, 2017 Luca Valenti Department of Pathophysiology
Demographics, tumor characteristics, treatment, and survival of patients with Klatskin tumors
ORIGINAL ARTICLE Annals of Gastroenterology (2018) 31, 1-6 Demographics, tumor characteristics, treatment, and survival of patients with Klatskin tumors Prabin Sharma a, Siddhartha Yadav b Yale New Haven
Viral hepatitis and Hepatocellular Carcinoma
Viral hepatitis and Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
Worldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC JORGE L. HERRERA, MD, MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE Worldwide Causes of HCC 60% 50% 40% 54% 30% 20% 10% 31% 15% 0% Hepatitis B Hepatitis
State of the Art Imaging for Hepatic Malignancy: My Assignment
State of the Art Imaging for Hepatic Malignancy: My Assignment CT vs MR vs MRCP Which one to choose for HCC vs Cholangiocarcinoma What special protocols to use for liver tumors Role of PET and Duplex US
APPENDIX ONE: ICD CODES
APPENDIX ONE: ICD CODES ICD-10-AM ICD-9-CM Malignant neoplasms C00 C97 140 208, 238.6, 273.3 Lip, oral cavity and pharynx C00 C14 140 149 Digestive organs C15 C26 150 157, 159 Oesophagus 4 C15 150 excluding
THE BURDEN OF CANCER IN NEBRASKA: RECENT INCIDENCE AND MORTALITY DATA
THE BURDEN OF CANCER IN NEBRASKA: RECENT INCIDENCE AND MORTALITY DATA Presented by: Bryan Rettig, MS Nebraska Dept. of Health & Human Services Division of Public Health May 31, 2017 Nebraska Cancer Registry
Potentially preventable cancers among Alaska Native people
Potentially preventable cancers among Alaska Native people Sarah Nash Cancer Surveillance Director, Alaska Native Tumor Registry Diana Redwood, Ellen Provost Alaska Native Epidemiology Center Cancer is
Radioembolization: technical aspects
Radioembolization: technical aspects Rita Golfieri Unità Operativa Radiologia Malpighi Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola - Malpighi La sottoscritta dichiara di non aver
Table E1. Standardized Mortality Ratios for Total and Specific Causes of Death Parameter Radiologists Psychiatrists No. of Deaths
RSNA, 2016 10.1148/radiol.2016152472 Table E1. Standardized Mortality Ratios for Total and Specific Causes of Death Parameter Radiologists Psychiatrists No. of Deaths Observed/Expected No. of Deaths Observed/Expected
Tumor Immunology. Tumor (latin) = swelling
Tumor Immunology Tumor (latin) = swelling benign tumor malignant tumor Tumor immunology : the study of the types of antigens that are expressed by tumors how the immune system recognizes and responds to
Liver Cancer And Tumours
Liver Cancer And Tumours What causes liver cancer? Many factors may play a role in the development of cancer. Because the liver filters blood from all parts of the body, cancer cells from elsewhere can
Proximal Bile Duct Cancer: Contemporary Management. William R. Jarnagin, MD, FACS
Proximal Bile Duct Cancer: Contemporary Management William R. Jarnagin, MD, FACS Biliary Tract Adenocarcinoma Spectrum of disease Intrahepatic (IHC) Hilar EH Gallbladder GB CBD Distal D PD Biliary Tract
Icd 10 code pancreatic cancer
Free, official coding info for 2018 ICD - 10 -CM C25.9 - includes detailed rules, notes, synonyms, ICD -9-CM conversion, index and annotation crosswalks, DRG grouping and. Free, official coding info for
Metabolic Syndrome and HCC. Jacob George
Metabolic Syndrome and HCC Jacob George MetS and risk of HCC and ICC All with HCC and ICC between 1993 and 2005 identified in the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. For
Cancers attributable to excess body weight in Canada in D Zakaria, A Shaw Public Health Agency of Canada
Cancers attributable to excess body weight in Canada in 2010 D Zakaria, A Shaw Public Health Agency of Canada Introduction Cancer is a huge burden in Canada: Nearly 50% of Canadians are expected to be
Hepatitis. Dr. Mohamed. A. Mahdi 5/2/2019. Mob:
Hepatitis Dr. Mohamed. A. Mahdi Mob: 0123002800 5/2/2019 Hepatitis Hepatitis means the inflammation of the liver. May cause by viruses or bacteria, parasites, radiation, drugs, chemical and toxins (alcohol).
Current Treatment Strategies for Hilar and Intrahepatic Cholangiocarcinoma
Current Treatment Strategies for Hilar and Intrahepatic Cholangiocarcinoma Jean-Nicolas Vauthey, MD, FACS Professor of Surgery Chief Hepato-Pancreato-Biliary Section Department of Surgical Oncology Crescent
/Webpages/zhang/chinese-full full- program.htm
http://www.ph.ucla.edu/epi/faculty/zhang /Webpages/zhang/chinese-full full- program.htm Cancer Incidence and Mortality and Risk Factors in the World Zuo-Feng Zhang, M.D., Ph.D. Fogarty International Training
Cancer in New Mexico 2017
Cancer in New Mexico 0 Please contact us! Phone: 0-- E-Mail: nmtr-info@salud.unm.edu URL: nmtrweb.unm.edu TABLE OF CONTENTS Introduction... New Cases of Cancer Estimated Number of New Cancer Cases Description
2011 to 2015 New Cancer Incidence Truman Medical Center - Hospital Hill
Number of New Cancers Truman Medical Center Hospital Hill Cancer Registry 2015 Statistical Summary Incidence In 2015, Truman Medical Center diagnosed and/or treated 406 new cancer cases. Four patients
Truman Medical Center-Hospital Hill Cancer Registry 2014 Statistical Summary Incidence
Truman Medical Center-Hospital Hill Cancer Registry 2014 Statistical Summary Incidence In 2014, there were 452 new cancer cases diagnosed and or treated at Truman Medical Center- Hospital Hill and an additional
Epidemiology of hepatocellular carcinoma and cholangiocarcinoma
1 Epidemiology of hepatocellular carcinoma and cholangiocarcinoma Jorge A. Marrero Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third cause of cancer-related deaths worldwide
Cancer in New Mexico 2014
Cancer in New Mexico 2014 Please contact us! Phone: 505-272-5541 E-Mail: info@nmtr.unm.edu http://som.unm.edu/nmtr/ TABLE OF CONTENTS Introduction... 1 New Cases of Cancer: Estimated Number of New Cancer
Worldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC Mark W. Russo, MD, MPH, FACG Carolinas HealthCare System Charlotte Worldwide Causes of HCC 60% 50% 40% 30% 20% 10% 0% 54% 31% 15% Hepatitis B Hepatitis C
GASTROINTESTINAL IMAGING STUDY GUIDE
GASTROINTESTINAL IMAGING STUDY GUIDE Pharynx Diverticula Foreign bodies Trauma o Motility Disorders Esophagus Diverticula Trauma Esophagitis Barrett esophagus Rings, webs, and strictures Varices Benign
A Time- and Resource-Efficient Method for Annually Auditing All Reporting Hospitals in Your State: the Inpatient & Outpatient Hospital Discharge Files
A Time- and Resource-Efficient Method for Annually Auditing All Reporting Hospitals in Your State: the Inpatient & Outpatient Hospital Discharge Files By Dr. Martin A. Whiteside Director, Office of Cancer
Biliary MRI w Eovist
Biliary MRI w Eovist Is there any added value? Elmar M. Merkle, MD Director of MR Imaging Duke University Medical Center elmar.merkle@duke.edu Declaration of Conflict of Interest or Relationship Research
Liver Cancer. Su Jong Yu, M.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine
Liver Cancer Su Jong Yu, M.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Primary Liver Cancer Hepatocellular carcinoma (HCC) : > 80% Derived
Intrahepatic, Perihilar and Distal Cholangiocarcinoma: Management and Outcomes
ORIGINAL ARTICLE January-February, Vol. 16 No. 1, 2017: 133-139 133 The Official Journal of the Mexican Association of Hepatology, the Latin-American Association for Study of the Liver and the Canadian
STOP Hepatocellular Carcinoma
STOP Hepatocellular Carcinoma Laura Tenner MD MPH, Amit G. Singal MD MS, Mamta Jain MD, Barbara Turner MD, Barbara Riske MS ReACH Center and Dept of Medicine UT Health San Antonio Dept of Medicine UT Southwestern
Hepatocytes produce. Proteins Clotting factors Hormones. Bile Flow
R.J.Bailey MD Hepatocytes produce Proteins Clotting factors Hormones Bile Flow Trouble.. for the liver! Trouble for the Liver Liver Gall Bladder Common Alcohol Hep C Fatty Liver Cancer Drugs Viruses Uncommon
Epidemiology of weak associations The case of nutrition and cancer. Paolo Boffetta Icahn School of Medicine at Mount Sinai New York NY
Epidemiology of weak associations The case of nutrition and cancer Paolo Boffetta Icahn School of Medicine at Mount Sinai New York NY Causality in epidemiology Epidemiology can lead to the identification
Autoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP
Autoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP Autoimmune hepatobiliary diseases The liver is an important target for immunemediated injury. Three disease phenotypes are recognized:
Alpha-fetoprotein
Other Names/Abbreviations AFP 190.25 - Alpha-fetoprotein Alpha-fetoprotein (AFP) is a polysaccharide found in some carcinomas. It is effective as a biochemical marker for monitoring the response of certain
Primary Sclerosing Cholangitis. Bibleclass Felix Brunner
Primary Sclerosing Cholangitis Bibleclass 29.04.2015 Felix Brunner Overview Epidemiology Pathogenesis Clinical Features, Genetics, Immunology Diagnosing PSC Treatment Medications, Transplantation Cancer-Risk
Tumor incidence varies significantly, depending on geographical location.
Hepatocellular carcinoma is the 5 th most common malignancy worldwide with male-to-female ratio 5:1 in Asia 2:1 in the United States Tumor incidence varies significantly, depending on geographical location.
American Cancer Society Estimated Cancer Deaths by Sex and Age (years), 2013
American Cancer Society Estimated Cancer Deaths by Sex and Age (years), 2013 All ages Younger than 45 45 and Older Younger than 65 65 and Older All sites, men 306,920 9,370 297,550 95,980 210,940 All sites,
*
Introduction Cancer is complex, can have many possible causes, and is increasingly common. For the U.S. population, 1 in 2 males and 1 in 3 females is at risk of developing cancer in their lifetime. The
*It can appear almost anywhere in the body. *The tumor can invade adjoining parts of the body and metastasize to other organs.
CANCER Cancer is an uncontrollable process of growth and cell dissemination. It can appear almost anywhere in the body. The tumor can invade adjoining parts of the body and metastasize to other organs.
Hepatocellular Carcinoma: Epidemiology and Screening
Hepatocellular Carcinoma: Epidemiology and Screening W. Ray Kim, MD Professor and Chief Gastroenterology and Hepatology Stanford University School of Medicine Case A 67 year old Filipino-American woman
A LEADER IN ADVANCED ENDOSCOPY AND HEPATOBILIARY SURGERY
A LEADER IN ADVANCED ENDOSCOPY AND HEPATOBILIARY SURGERY St. Peter s Hospital Advanced Endoscopy & Hepatobiliary Center Welcome The St. Peter s Hospital Advanced Endoscopy & Hepatobiliary Center is a leader
Appendix 5. EFSUMB Newsletter. Gastroenterological Ultrasound
EFSUMB Newsletter 87 Examinations should encompass the full range of pathological conditions listed below A log book listing the types of examinations undertaken should be kept Training should usually
Liver surgery, acute GI tract bleeding
Semmelweis University, Faculty of Medicine, 1 st Department of Surgery Liver surgery, acute GI tract bleeding Oszkár HAHN M.D. LIVER CYST US, CT, MRI Parasite (ELISA, eosinophil, anaphylaxy) Echinococcus
Estimated Minnesota Cancer Prevalence, January 1, MCSS Epidemiology Report 04:2. April 2004
MCSS Epidemiology Report 04:2 Suggested citation Perkins C, Bushhouse S.. Minnesota Cancer Surveillance System. Minneapolis, MN, http://www.health.state.mn.us/divs/hpcd/ cdee/mcss),. 1 Background Cancer
Detection: Rabab Gaafar,MD. Prof. Medical Oncology NCI,Cairo, Cairo University
Cancer Prevention and Early Detection: Rabab Gaafar,MD Prof. Medical Oncology NCI,Cairo, Cairo University Director Early Detection Unit Prevention and Early Detection Definition Goals of Cancer Prevention
The clinical presentation and prognostic factors for intrahepatic and extrahepatic cholangiocarcinoma in a tertiary care centre
Alimentary Pharmacology & Therapeutics The clinical presentation and prognostic factors for intrahepatic and extrahepatic cholangiocarcinoma in a tertiary care centre A. G. SINGAL*, M. O. RAKOSKI*, R.
The main credit of this work would go to the team of cancer epidemiology department without them this report would have never come into light.
Acknowledgment The main credit of this work would go to the team of cancer epidemiology department without them this report would have never come into light. Special appreciation goes to: Prof Amal Samy
National Cancer Statistics in Korea, 2014
National Cancer Statistics in Korea, 2014 2016. 12. 20. Korea Central Cancer Registry Cancer Incidence in Korea, 2014 National Cancer Incidence, 2014 Trends in Cancer Incidence by Sex and Year * Dark colored
La riattivazione dell epatite virale nel paziente in terapia biologica
La riattivazione dell epatite virale nel paziente in terapia biologica Claudio Puoti S.C. di Medicina Interna e Medicina Epato-Gastroenterologica Osp. di Marino-Frascati - Roma Patterns of HBV-related
CEA (CARCINOEMBRYONIC ANTIGEN)
(CARCINOEMBRYONIC ANTIGEN) 428 C15.3 Malignant neoplasm of upper third of esophagus C15.4 Malignant neoplasm of middle third of esophagus C15.5 Malignant neoplasm of lower third of esophagus C15.8 Malignant
Chronic Cholestatic Liver Diseases
Chronic Cholestatic Liver Diseases - EASL Clinical Practice Guidelines - Rome, 8 October 2010 Ulrich Beuers Department of Gastroenterology and Hepatology Tytgat Institute of Liver and Intestinal Research
Hepato-Pancreatico-Biliary Surgery. Dr. Ankur J. Shah. MS, DNB, MNAMS, MRCSEd (UK), FRCS (UK)
Hepato-Pancreatico-Biliary Surgery Dr. Ankur J. Shah MS, DNB, MNAMS, MRCSEd (UK), FRCS (UK) Consultant Hepato-Pancreatico-Biliary and Liver Transplant Surgeon Ansh Liver Clinic Prevention to Cure Address